Phillips-Medisize congratulates ivWatch on their recent recognition as a finalist in Medical Design Excellence Awards (MDEA).
ivWatch LLC is a nominee for the Model 400 device in the nonsurgical hospital supplies and equipment category. Winners will be announced on June 13 in New York during a ceremony at MD&M East.
The ivWatch Model 400 is a device that continuously monitors a patient’s peripheral IV for the early detection of infiltrations – when medication or fluid leaks outside the vein into the surrounding tissue.
Intravenous therapy is a routine part of treatment for nearly 80% of patients in the U.S., and more than 20% of these IVs may fail because of infiltration. Because every IV failure risks both a serious drug delivery error and tissue damage, earlier detection of those failures is the new and next step for minimizing this potential for patient harm.
“We have partnered with ivWatch since 2011 on development and production, so it is a true privilege to be recognized as a supplier for their program. They are a great example of a company that utilized our full capabilities, from design to manufacturing,” said Matt Jennings, chairman and CEO of Phillips-Medisize (Hudson, Wis.).
“Phillips-Medisize has been a valued partner in getting the ivWatch Model 400 to market. We have leveraged their design and manufacturing expertise to solve a significant medical issue,” said Gary Warren, ivWatch president & CEO. “It is a pleasure to be able to recognize the team at Phillips-Medisize as one of our honored suppliers for the MDEA Competition.”
Phillips-Medisize
